Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1176/appi.ajp.2008.08091427 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Memantine Inhibits Calcium-Permeable AMPA Receptors.
bioRxiv
July 2024
Center for Membrane Biology, Department of Biochemistry and Molecular Biology, University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
Memantine is an US Food and Drug Administration (FDA) approved drug that selectively inhibits NMDA-subtype ionotropic glutamate receptors (NMDARs) for treatment of dementia and Alzheimer's. NMDARs enable calcium influx into neurons and are critical for normal brain function. However, increasing evidence shows that calcium influx in neurological diseases is augmented by calcium-permeable AMPA-subtype ionotropic glutamate receptors (AMPARs).
View Article and Find Full Text PDFPediatric Treatment-Resistant Obsessive Compulsive Disorder: Treatment Options and Challenges.
Paediatr Drugs
July 2024
Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, 1977 Butler Blvd, Suite 4-400, Houston, TX, 77030, USA.
Article Synopsis
- Pediatric OCD is a serious mental health condition that can be hard to treat, and about 10% of kids don't get better with standard treatments.
- Researchers looked at different ways to help those kids who don't respond to normal treatments, including learning from studies done on adults.
- The most promising options for treating these kids include special intensive programs and using certain medications alongside antidepressants, but more research is needed to find the best solutions.
Augmentation Strategies for Partial or Non-responders to Clozapine in Patients with Schizophrenia: A Bayesian Network Meta-analysis of Randomized Controlled Trials.
Clin Psychopharmacol Neurosci
May 2024
Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Bhubaneswar, India.
Clozapine is the only approved drug for treatment-resistant schizophrenia, but the response to the drug is often inadequate. Augmentation with other antipsychotics, anticonvulsants, and antidepressants is recommended for such patients, but there is a lack of evidence regarding the most effective therapy. This network meta-analysis was conducted to evaluate the efficacy of pharmacological agents used in the augmentation strategies in patients who were partial/ non-responders to clozapine.
View Article and Find Full Text PDFManaging Opioid Withdrawal Symptoms During the Fentanyl Crisis: A Review.
Subst Abuse Rehabil
April 2024
Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA.
Illicitly manufactured fentanyl (IMF) is a significant contributor to the increasing rates of overdose-related deaths. Its high potency and lipophilicity can complicate opioid withdrawal syndromes (OWS) and the subsequent management of opioid use disorder (OUD). This scoping review aimed to collate the current OWS management of study populations seeking treatment for OWS and/or OUD directly from an unregulated opioid supply, such as IMF.
View Article and Find Full Text PDFComprehensive evaluation of 45 augmentation drugs for schizophrenia: a network meta-analysis.
EClinicalMedicine
March 2024
UR3279, CEReSS, Research Centre on Health Services and Quality of Life, Aix Marseille University, Marseille, France.
Background: Antipsychotics are the gold standard treatment for schizophrenia, but many patients who receive treatment experience persistent symptoms. The aim of this network meta-analysis was to determine the efficacy of augmentation drugs for the treatment of schizophrenia.
Methods: In accordance with the PRISMA statement, the PubMed, Web of Science, Google Scholar, CENTRAL, clinical trial and EUDRACT databases were searched from inception to May 15th, 2023.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!